Fig. 2.

Viability studies with Peptide 14 tested on different cancer cell lines. Different cancer cell lines were exposed to Peptide 14 (A) or Doxorubicin (B) at increasing concentrations and cell viability was assessed after 24 h using MTT assay. All experiments were performed in triplicate and were analyzed using ONE way anova and Bonferroni post-hoc test.*p < 0.5, * *p < 0.01, * **p < 0.001; * ** *p < 0.0001, represents a significant difference compared to untreated controls.